GlassScriptPhysician profile
James Davis
NPI 1780905083
$434.81
in general payments reported to CMS, 2019-2025
10 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.59 · 2023: $66.63 · 2024: $151 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $86.40 | 2023-2025 | Rotarix, Bexsero, Penmenvy |
| Collegium Pharmaceutical, INC. | $61.77 | 2025 | Jornay Pm |
| Kaleo, INC. | $58.05 | 2019-2024 | Auvi-Q |
| Seqirus USA INC | $49.37 | 2025 | Flucelvax |
| Merck Sharp & Dohme LLC | $41.56 | 2024 | Vaxneuvance, Gardasil 9, M-M-R II |
| Ironshore Pharmaceuticals INC. | $38.62 | 2019-2024 | |
| Alk-Abello, INC | $37.03 | 2025 | Neffy, Odactra, Grastek |
| Phadia US INC. | $23.93 | 2024 | Immunocap |
| Supernus Pharmaceuticals, INC. | $20.46 | 2024 | Qelbree |
| Sanofi Pasteur INC. | $17.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.